Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A placebo controlled, double-blind investigation of the therapeutic utility of Xolair (omalizumab) for attenuating aspirin induced bronchospasm in patients with aspirin exacerbated respiratory disease (AERD) undergoing aspirin desensitization

Next Previous
Trial Profile

A placebo controlled, double-blind investigation of the therapeutic utility of Xolair (omalizumab) for attenuating aspirin induced bronchospasm in patients with aspirin exacerbated respiratory disease (AERD) undergoing aspirin desensitization

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 10 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Omalizumab (Primary)
  • Indications Aspirin-induced asthma
  • Focus Therapeutic Use

    • Most Recent Events

    • 16 May 2018 Primary endpoint (Spirometry (FEV1) testing to assess the efficacy of Xolair on aspirin induced bronchospasm during aspirin desensitization in patients with AERD) has been met, according to results published in the Annals of Allergy, Asthma and Immunology.
    • 16 May 2018 Results (n=16) assessing whether omalizumab administration would be associated with attenuation of aspirin provoked bronchospasm in patients with AERD undergoing aspirin desensitization, were published in the Annals of Allergy, Asthma and Immunology.
    • 07 Mar 2016 Results presented at the 2016 Annual Meeting of the American Academy of Allergy, Asthma and Immunology
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top